TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics Limited announced the issuance of 12,942,721 unquoted equity securities in the form of options expiring on November 17, 2029, with an exercise price of $0.10. This move is part of an employee incentive scheme and is not intended for quotation on the ASX, reflecting the company’s strategy to incentivize and retain talent, potentially impacting its operational capabilities and market position.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of innovative cancer therapies. The company’s primary products include targeted and personalized medicine solutions aimed at improving cancer treatment outcomes.
Average Trading Volume: 816,713
Technical Sentiment Signal: Buy
Current Market Cap: A$49.42M
Find detailed analytics on PTX stock on TipRanks’ Stock Analysis page.